Prognostic value of EIF5A2 in solid tumors: A meta-analysis and bioinformatics analysis-Reference-Cited by-同舟云学术

Prognostic value of EIF5A2 in solid tumors: A meta-analysis and bioinformatics analysis

Published:2024-01-01 Issue:1 Volume:19 Page:
ISSN:2391-5463
Container-title:Open Medicine
language:en
Short-container-title:

Author:

Fang Jianwen¹,Yu Tianze¹,Jiang Xiaocong¹,Lu Yuexin¹,Shang Xi²,Shen Haixing¹³,Lu Yue⁴,Zheng Jingyan⁵,Fu Peifen¹

Affiliation:

1. Department of Breast Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine , Hangzhou , 310003 , China

2. Department of Breast and Thyroid Surgery, Taizhou Hospital, Zhejiang University , Taizhou , Zhejiang, 318000 , China

3. Department of Breast and Thyroid Surgery, Cixi People’s Hospital , Cixi , Zhejiang, 315300 , China

4. Department of Breast and Thyroid Surgery, First Affiliated Hospital of Huzhou University , Huzhou , 313000, Zhejiang , China

5. Department of Breast and Thyroid Surgery, Lishui People’s Hospital, The Six Affiliated Hospital of Wenzhou Medical University , Lishui , Zhejiang, 323000 , China

Abstract

Abstract Aims In cancer biology, the aberrant overexpression of eukaryotic translation initiation factor 5A2 (EIF5A2) has been correlative with an ominous prognosis, thereby underscoring its pivotal role in fostering metastatic progression. Consequently, EIF5A2 has garnered significant attention as a compelling prognostic biomarker for various malignancies. Our research endeavors were thus aimed at elucidating the utility and significance of EIF5A2 as a robust indicator of cancer outcome prediction. Method An exhaustive search of the PubMed, EMBASE, and Web of Science databases found relevant studies. The link between EIF5A2 and survival prognosis was examined using hazard ratios and 95% confidence intervals. Subsequently, The Cancer Genome Atlas (TCGA) and the Gene Expression Profiling Interactive Analysis (GEPIA) databases were employed to validate EIF5A2 expression across various cancer types. Results Through pooled analysis, we found that increased EIF5A2 expression was significantly associated with decreased overall survival (OS) and disease-free survival/progression-free survival/relapse-free survival (DFS/PFS/RFS). Moreover, TCGA analysis revealed that EIF5A2 was significantly upregulated in 27 types of cancer, with overexpression being linked to shorter OS in three, worse DFS in two, and worse PFS in six types of cancer. GEPIA showed that patients with EIF5A2 overexpression had reduced OS and DFS. Conclusions In solid tumors, EIF5A2 emerges as a reliable prognostic marker. Our meta-analysis comprehensively analyzed the prognostic value of EIF5A2 in solid tumors and assessed its efficacy as a predictive marker.

Publisher

Walter de Gruyter GmbH

Link

https://www.degruyter.com/document/doi/10.1515/med-2024-0962/pdf

Reference35 articles.

1. Jenkins ZA, Hååg PG, Johansson HE. Human eIF5A2 on chromosome 3q25-q27 is a phylogenetically conserved vertebrate variant of eukaryotic translation initiation factor 5A with tissue-specific expression. Genomics. 2001;71(1):101–9. 10.1006/geno.2000.6418.

2. Yang SH, Hu S, Kang Q, Liu LX, Wei Q, Song ZM, et al. EIF5A2 promotes proliferation and invasion of intrahepatic cholangiocarcinoma cells. Clin Res Hepatol Gastroenterol. 2022;46(7):101991. 10.1016/j.clinre.2022.101991.

3. Gundamaraju R, Lu W, Paul MK, Jha NK, Gupta PK, Ojha S, et al. Autophagy and EMT in cancer and metastasis: Who controls whom? Biochim Biophys Acta Mol Basis Dis. 2022;1868(9):166431. 10.1016/j.bbadis.2022.166431.

4. Zhao G, Zhang W, Dong P, Watari H, Guo Y, Pfeffer LM, et al. EIF5A2 controls ovarian tumor growth and metastasis by promoting epithelial to mesenchymal transition via the TGFβ pathway. Cell Biosci. 2021;11(1):70. 10.1186/s13578-021-00578-5.

5. Zhong X, Xiu H, Bi Y, Zhang H, Chang L, Diao H. Targeting eIF5A2 inhibits prostate carcinogenesis, migration, invasion and metastasis in vitro and in vivo. Bioengineered. 2020;11(1):619–27. 10.1080/21655979.2020.1774993.